Diego Esteban Cargnelutti1, María Cristina Salomón2, Verónica Celedon3, María Fernanda García Bustos4, Gastón Morea2, Fernando Darío Cuello-Carrión3, Eduardo Alberto Scodeller3. 1. Instituto de Medicina y Biología Experimental de Cuyo (IMBECU), Centro Científico y Tecnológico de Mendoza, Consejo Nacional de Investigaciones Científicas y Técnicas, Mendoza, Argentina; Área de Parasitología, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina. Electronic address: diegocargnelutti@hotmail.com. 2. Área de Parasitología, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina. 3. Instituto de Medicina y Biología Experimental de Cuyo (IMBECU), Centro Científico y Tecnológico de Mendoza, Consejo Nacional de Investigaciones Científicas y Técnicas, Mendoza, Argentina. 4. Instituto de Patología Experimental (IPE), Centro Científico y Tecnológico de Salta, Consejo Nacional de Investigaciones Científicas y Técnicas, Salta, Argentina.
Abstract
BACKGROUND/ PURPOSE: A proper adjuvant has a relevant role in vaccine formulations to generate an effective immune response. In this study, total Leishmania antigen (TLA) formulated with Montanide ISA 763 or R848 as adjuvants were evaluated as a first generation Leishmania vaccine in a murine model. METHODS: Immunization protocols were tested in BALB/c mice with a subcutaneous prime/boost regimen with an interval of 3 weeks. Mice immunized with unadjuvanted TLA and phosphate-buffered saline (PBS) served as control groups. On Day 21 and Day 36 of the protocol, we evaluated the humoral immune response induced by each formulation. Fifteen days after the boost, the immunized mice were challenged with 1 × 10(5) promastigotes of Leishmania (Leishmania) amazonensis in the right footpad (RFP). The progress of the infection was followed for 10 weeks; at the end of this period, histopathological studies were performed in the RFP. RESULTS: Vaccines formulated with Montanide ISA 763 generated an increase in the production of immunoglobulin G (IgG; p < 0.05) compared with the control group. There were no statistically significant differences in IgG1 production between the study groups. However, immunization with TLA-Montanide ISA 763 resulted in an increase in IgG2a compared to the unadjuvanted control (p < 0.001). Also noteworthy was the fact that a significant reduction in swelling and histopathological damage of the RFP was recorded with the Montanide ISA 763 formulation. CONCLUSION: We conclude that the immunization of BALB/c mice with a vaccine formulated with TLA and Montanide ISA 763 generated a protective immune response against L. (L.) amazonensis, characterized by an intense production of IgG2a.
BACKGROUND/ PURPOSE: A proper adjuvant has a relevant role in vaccine formulations to generate an effective immune response. In this study, total Leishmania antigen (TLA) formulated with Montanide ISA 763 or R848 as adjuvants were evaluated as a first generation Leishmania vaccine in a murine model. METHODS: Immunization protocols were tested in BALB/c mice with a subcutaneous prime/boost regimen with an interval of 3 weeks. Mice immunized with unadjuvanted TLA and phosphate-buffered saline (PBS) served as control groups. On Day 21 and Day 36 of the protocol, we evaluated the humoral immune response induced by each formulation. Fifteen days after the boost, the immunized mice were challenged with 1 × 10(5) promastigotes of Leishmania (Leishmania) amazonensis in the right footpad (RFP). The progress of the infection was followed for 10 weeks; at the end of this period, histopathological studies were performed in the RFP. RESULTS: Vaccines formulated with Montanide ISA 763 generated an increase in the production of immunoglobulin G (IgG; p < 0.05) compared with the control group. There were no statistically significant differences in IgG1 production between the study groups. However, immunization with TLA-Montanide ISA 763 resulted in an increase in IgG2a compared to the unadjuvanted control (p < 0.001). Also noteworthy was the fact that a significant reduction in swelling and histopathological damage of the RFP was recorded with the Montanide ISA 763 formulation. CONCLUSION: We conclude that the immunization of BALB/c mice with a vaccine formulated with TLA and Montanide ISA 763 generated a protective immune response against L. (L.) amazonensis, characterized by an intense production of IgG2a.
Authors: María José Germanó; Juan Pablo Mackern-Oberti; Jessica Gardone Vitório; Mariana Costa Duarte; Daniel Carvalho Pimenta; Maria Victoria Sanchez; Flavia Alejandra Bruna; Esteban Sebastián Lozano; Ana Paula Fernandes; Diego Esteban Cargnelutti Journal: Front Immunol Date: 2022-05-12 Impact factor: 8.786
Authors: Federico Leonel Parra; Ayelen Tatiana Caimi; Maria Julia Altube; Diego Esteban Cargnelutti; Mónica Elba Vermeulen; Marcelo Alexandre de Farias; Rodrigo Villares Portugal; Maria Jose Morilla; Eder Lilia Romero Journal: Front Bioeng Biotechnol Date: 2018-11-06